Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study
| Autor: | Xiaoyou Chen, Shouguo Pan, Lei Gao, Xueling Guan, Qi Jin, Xiangwei Li, Fei Shen, Jiaoxia Yan, Boxuan Feng, Hengjing Li, Dakuan Wang, Yu Ma, Xuefang Cao, Jianmin Liu, Ling Guan, Henan Xin, Zisen Liu, Zongde Zhang, Yu Chen, Xin-hua Zhou, Haoran Zhang, Wei Cui |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male Rural Population medicine.medical_specialty China Drug Administration Schedule law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Latent Tuberculosis Risk Factors Internal medicine medicine Isoniazid Humans 030212 general & internal medicine Adverse effect Antibiotics Antitubercular Aged Proportional Hazards Models Latent tuberculosis business.industry Hazard ratio Mycobacterium tuberculosis Middle Aged medicine.disease Rifapentine Clinical trial Regimen Treatment Outcome 030228 respiratory system Communicable Disease Control Drug Therapy Combination Female Rifampin business medicine.drug |
| Zdroj: | The European respiratory journal. 52(6) |
| ISSN: | 1399-3003 |
| Popis: | Latent tuberculosis infection (LTBI) management is now a critical component of the World Health Organization's End TB Strategy.In this randomised controlled trial (Chinese Clinical Trial Registry identifier ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid (a 3-month once-weekly regimen and a 2-month twice-weekly regimen) were initially designed to be evaluated for rural residents aged 50–69 years with LTBI in China.Due to the increasingly rapid growth and unexpected high frequency of adverse effects, the treatments were terminated early (after 8 weeks for the once-weekly regimen and after 6 weeks for the twice-weekly regimen). In the modified intention-to-treat analysis on the completed doses, the cumulative rate of active disease during 2 years of follow-up was 1.21% (14 out of 1155) in the untreated controls, 0.78% (10 out of 1284) in the group that received the 8-week once-weekly regimen and 0.46% (six out of 1299) in the group that received the 6-week twice-weekly regimen. The risk of active disease was decreased, with an adjusted hazard ratio of 0.63 (95% CI 0.27–1.43) and 0.41 (95% CI 0.15–1.09) for the treatments, respectively. No significant difference was found in the occurrence of hepatotoxicity (1.02% (13 out of 1279) versus 1.17% (15 out of 1279); p=0.704).The short regimens tested must be used with caution among the elderly because of the high rates of adverse effects. Further work is necessary to test the ultrashort regimens in younger people with LTBI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|